2.
G9a的表达与乳腺癌临床病理特征的关系
Relationship between G9a expression and clinicopathological features of breast
| Clinicopathological parameters | Number of cases | Expression of G9a | χ2 | P | |
| Positive (%) | Negative (%) | ||||
| Age (year) | |||||
| ≤ 35 | 9 | 9 (100.0%) | 0 (0.0%) | 6.188 | 0.042 |
| >35-55 | 83 | 54 (65.1%) | 29 (34.9%) | ||
| >55 | 30 | 17 (56.7%) | 13 (43.3%) | ||
| Menopausal status | |||||
| Premenopause | 71 | 50 (70.4%) | 21 (29.6%) | 1.769 | 0.184 |
| Postmenopause | 51 | 30 (58.8%) | 21 (41.2%) | ||
| Family history of cancer | |||||
| Non-existent | 110 | 71 (64.5%) | 39 (35.6%) | 0.524 | 0.469 |
| Existent | 12 | 9 (75.0%) | 3 (25.0%) | ||
| Pathological type | |||||
| Carcinoma in situ | 3 | 2 (66.7%) | 1 (33.3%) | 21.748 | < 0.001 |
| Invasive ductal carcinoma | 87 | 64 (73.6%) | 23 (26.4%) | ||
| Invasive lobular carcinoma | 22 | 5 (22.7%) | 17 (77.3%) | ||
| Other types of cancer | 10 | 9 (90.0%) | 1 (10.0%) | ||
| Maximum diameter of tumors (cm) | |||||
| ≤ 2 | 77 | 49 (63.6%) | 28 (36.4%) | 0.757 | 0.799 |
| 2-5 | 44 | 30 (68.2%) | 14 (31.8%) | ||
| >5 | 1 | 1 (100.0%) | 0 (0.0%) | ||
| Lymph node metastasis | |||||
| Non-existent | 68 | 40 (58.8%) | 28 (41.2%) | 3.101 | 0.078 |
| Existent | 54 | 40 (74.1%) | 14 (25.9%) | ||
| Lymphatic metastasis | |||||
| N1 | 30 | 21 (70.0%) | 9 (30.0%) | 5.434 | 0.057 |
| N2 | 19 | 17 (89.5%) | 2 (10.5%) | ||
| N3 | 5 | 2 (40.0%) | 3 (60.0%) | ||
| Histological grading | |||||
| Level Ⅰ | 16 | 12 (75.0%) | 4 (25.0%) | 2.083 | 0.353 |
| Level Ⅱ | 48 | 31 (64.6%) | 17 (35.4%) | ||
| Level Ⅲ | 41 | 32 (78.0%) | 9 (22.0%) | ||
| Stage of pTNM | |||||
| Stage 0 | 4 | 3 (75.0%) | 1 (25.0%) | 5.821 | 0.177 |
| Stage Ⅰ | 42 | 23 (54.8%) | 19 (45.2%) | ||
| Stage Ⅱ | 51 | 34 (66.7%) | 17 (33.3%) | ||
| Stage Ⅲ | 23 | 19 (82.6%) | 4 (17.4%) | ||
| Stage Ⅳ | 2 | 1 (50.0%) | 1 (50.0%) | ||